Insellar

Insellar operates at the intersection of neurotechnology, medical devices, digital health, and therapeutics. Its stated distinction is an approach to brain-computer interfaces that modulates brain activity while working with the body’s own systems, with an emphasis on minimally invasive, physiological mental-health treatment. The company identifies major depressive disorder and other mental-health conditions as areas of focus. It also does not specify a device design, stimulation method, clinical evidence, regulatory status, or commercial product that would establish a defensible technical or market advantage. Insellar is at an early stage: it was founded in 2025 and announced a €400,000 pre-seed round led by IBB Ventures in April 2026. That profile is consistent with a company developing its technology and seeking engagement from investors, clinicians, and patients, rather than an established medical-device supplier. Its competitive position will depend on validation of its approach and progress toward clinical use.

Insellar’s disclosed trajectory is that of a recently formed, pre-seed neurotechnology company. It was founded in 2025, and Hamed Bahmani’s founder and CEO role is listed as beginning in August 2025. On Apr 13, 2026, the company announced a €400,000 pre-seed round led by IBB Ventures, equivalent to approximately $467,760. This is the only listed funding round and provides a clear financing inflection point, although no use of proceeds, runway, or subsequent financing is specified. Public coverage on May 19, 2026 included Insellar among five new startups, indicating early visibility following the funding announcement. The company’s stated development focus is a patented brain-computer interface that modulates brain activity and aims to work with the body’s own systems, with minimally invasive approaches for mental-health conditions including major depressive disorder. No product launch, clinical trial milestone, regulatory clearance, hiring plan, or employee-growth trend is disclosed. As a result, evidence of progress currently centers on company formation, initial financing, and the articulation of a technical and therapeutic direction. Future assessment will hinge on concrete product details and clinical validation.